Liver Cirrhosis-Pipeline Review, H1 2017

Liver Cirrhosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9072IDB
  • |
  • Pages: 96
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Liver Cirrhosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis-Pipeline Review, H1 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Liver Cirrhosis-Overview

Liver Cirrhosis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Cirrhosis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Cirrhosis-Companies Involved in Therapeutics Development

Conatus Pharmaceuticals Inc

Galectin Therapeutics Inc

Gilead Sciences Inc

Human Stem Cells Institute

International Stem Cell Corp

Ocera Therapeutics Inc

Pharmicell Co Ltd

S-Evans Biosciences Inc

Stelic Institute & Co Inc

Stempeutics Research Pvt Ltd

VESSL Therapeutics Ltd

Liver Cirrhosis-Drug Profiles

BCD-800-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Cirrhosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-LC-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gemacell-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMCT-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXHPC-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-654-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Cirrhosis and Rheumatoid Arthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stempeucel-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STNM-04-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Cirrhosis-Dormant Projects

Liver Cirrhosis-Discontinued Products

Liver Cirrhosis-Product Development Milestones

Featured News & Press Releases

Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting

Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data

Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting

Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting

Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Liver Cirrhosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Liver Cirrhosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Liver Cirrhosis-Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Liver Cirrhosis-Pipeline by Galectin Therapeutics Inc, H1 2017

Liver Cirrhosis-Pipeline by Gilead Sciences Inc, H1 2017

Liver Cirrhosis-Pipeline by Human Stem Cells Institute, H1 2017

Liver Cirrhosis-Pipeline by International Stem Cell Corp, H1 2017

Liver Cirrhosis-Pipeline by Ocera Therapeutics Inc, H1 2017

Liver Cirrhosis-Pipeline by Pharmicell Co Ltd, H1 2017

Liver Cirrhosis-Pipeline by S-Evans Biosciences Inc, H1 2017

Liver Cirrhosis-Pipeline by Stelic Institute & Co Inc, H1 2017

Liver Cirrhosis-Pipeline by Stempeutics Research Pvt Ltd, H1 2017

Liver Cirrhosis-Pipeline by VESSL Therapeutics Ltd, H1 2017

Liver Cirrhosis-Dormant Projects, H1 2017

Liver Cirrhosis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Conatus Pharmaceuticals Inc, Galectin Therapeutics Inc, Gilead Sciences Inc, Human Stem Cells Institute, International Stem Cell Corp, Ocera Therapeutics Inc, Pharmicell Co Ltd, S-Evans Biosciences Inc, Stelic Institute & Co Inc, Stempeutics Research Pvt Ltd, VESSL Therapeutics Ltd

Liver Cirrhosis Therapeutic Products under Development, Key Players in Liver Cirrhosis Therapeutics, Liver Cirrhosis Pipeline Overview, Liver Cirrhosis Pipeline, Liver Cirrhosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 128700
Site License
USD 4000 INR 257400
Corporate User License
USD 6000 INR 386100

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com